kr299.60
0.13% today
Stockholm, Oct 13, 05:30 pm CET
ISIN
SE0000872095
Symbol
SOBI

Swedish Orphan Biovitrum Stock price

kr299.60
+26.60 9.74% 1M
+38.20 14.61% 6M
-17.80 5.61% YTD
+3.40 1.15% 1Y
+77.00 34.59% 3Y
+121.60 68.31% 5Y
+183.10 157.17% 10Y
+188.10 168.70% 20Y
Stockholm, Closing price Mon, Oct 13 2025
-0.40 0.13%
ISIN
SE0000872095
Symbol
SOBI
Industry

Key metrics

Basic
Market capitalization
kr105.2b
Enterprise Value
kr116.9b
Net debt
kr11.8b
Cash
kr1.1b
Shares outstanding
344.6m
Valuation (TTM | estimate)
P/E
23.8 | 21.0
P/S
3.9 | 3.6
EV/Sales
4.3 | 4.0
EV/FCF
30.0
P/B
2.7
Financial Health
Equity Ratio
53.4%
Return on Equity
9.6%
ROCE
11.4%
ROIC
9.3%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
kr27.0b | kr28.9b
EBITDA
kr10.0b | kr10.6b
EBIT
kr6.4b | kr6.9b
Net Income
kr4.4b | kr4.9b
Free Cash Flow
kr3.9b
Growth (TTM | estimate)
Revenue
13.8% | 11.0%
EBITDA
23.8% | 11.0%
EBIT
41.7% | 18.9%
Net Income
103.9% | 26.5%
Free Cash Flow
-22.9%
Margin (TTM | estimate)
Gross
78.5%
EBITDA
37.0% | 36.6%
EBIT
23.8%
Net
16.2% | 17.0%
Free Cash Flow
14.5%
More
EPS
kr12.6
FCF per Share
kr11.3
Short interest
-
Employees
2k
Rev per Employee
kr13.7m
Show more

Is Swedish Orphan Biovitrum a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.

Swedish Orphan Biovitrum Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Swedish Orphan Biovitrum forecast:

13x Buy
68%
5x Hold
26%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a Swedish Orphan Biovitrum forecast:

Buy
68%
Hold
26%
Sell
5%

Financial data from Swedish Orphan Biovitrum

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
26,969 26,969
14% 14%
100%
- Direct Costs 5,804 5,804
10% 10%
22%
21,165 21,165
15% 15%
78%
- Selling and Administrative Expenses 7,746 7,746
10% 10%
29%
- Research and Development Expense 3,443 3,443
6% 6%
13%
9,966 9,966
24% 24%
37%
- Depreciation and Amortization 3,551 3,551
1% 1%
13%
EBIT (Operating Income) EBIT 6,415 6,415
42% 42%
24%
Net Profit 4,372 4,372
104% 104%
16%

In millions SEK.

Don't miss a Thing! We will send you all news about Swedish Orphan Biovitrum directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. The firm focuses on the hematology and immunology therapeutic areas. It also offers specialty treatments in the area of genetics and metabolism. The company was founded in 2001 and is headquartered in Solna, Sweden.

Head office Sweden
CEO Guido Oelkers
Employees 1,895
Founded 2001
Website www.sobi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today